Comparison of two targeted ultra-deep sequencing technologies for analysis of plasma circulating tumour DNA in endocrine-therapy-resistant breast cancer patients.
- Abstract:
- PURPOSE: There is growing interest in the application of circulating tumour DNA (ctDNA) as a sensitive tool for monitoring tumour evolution and guiding targeted therapy in patients with cancer. However, robust comparisons of different platform technologies are still required. Here we compared the InVisionSeq™ ctDNA Assay with the Oncomine™ Breast cfDNA Assay to assess their concordance and feasibility for the detection of mutations in plasma at low (
- Authors:
- G Nteliopoulos, K Page, A Hills, K Howarth, W Emmett, E Green, LJ Martinson, D Fernadez-Garcia, R Hastings, DS Guttery, L Kenny, J Stebbing, S Cleator, F Rehman, KLT Gleason, A Sanela, C Ion, AJ Rushton, N Rosenfeld, RC Coombes, JA Shaw
- Journal:
- Breast Cancer Res Treat
- Citation info:
- 188(2):465-476
- Publication date:
- 1st Jul 2021
- Full text
- DOI